These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17323424)

  • 21. Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway.
    Miao Q; Hao S; Li H; Sun F; Wang X
    Int J Clin Exp Pathol; 2015; 8(9):10460-7. PubMed ID: 26617755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RANK/RANKL/OPG system in the intervertebral disc.
    Takegami N; Akeda K; Yamada J; Sano T; Murata K; Huang J; Masuda K; Sudo A
    Arthritis Res Ther; 2017 Jun; 19(1):121. PubMed ID: 28576140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment.
    Huang L; Cheng YY; Chow LT; Zheng MH; Kumta SM
    Mol Pathol; 2003 Apr; 56(2):116-20. PubMed ID: 12665629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
    Armada L; Marotta Pdos S; Pires FR; Siqueira JF
    J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Localization of RANK, RANKL and osteoprotegerin during healing of surgically created periodontal defects in sheep.
    Baharuddin NA; Coates DE; Cullinan M; Seymour G; Duncan W
    J Periodontal Res; 2015 Apr; 50(2):211-9. PubMed ID: 24948035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology.
    Melchiorre D; Milia AF; Linari S; Romano E; Benelli G; Manetti M; Guiducci S; Ceccarelli C; Innocenti M; Carulli C; Civinini R; Morfini M; Matucci-Cerinic M; Ibba-Manneschi L
    J Rheumatol; 2012 Aug; 39(8):1678-86. PubMed ID: 22753650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
    Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors.
    Toma CD; Svoboda M; Arrich F; Ekmekcioglu C; Assadian O; Thalhammer T
    J Pineal Res; 2007 Sep; 43(2):206-13. PubMed ID: 17645699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Wenyangbushen formula on the expression of VEGF, OPG, RANK and RANKL in rabbits with steroid-induced femoral head avascular necrosis.
    Song HM; Wei YC; Li N; Wu B; Xie N; Zhang KM; Wang SZ; Wang HM
    Mol Med Rep; 2015 Dec; 12(6):8155-61. PubMed ID: 26496816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OPG, RANK and RANK ligand expression in thyroid lesions.
    Heymann MF; Riet A; Le Goff B; Battaglia S; Paineau J; Heymann D
    Regul Pept; 2008 Jun; 148(1-3):46-53. PubMed ID: 18367263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RANK and RANK ligand expression in primary human osteosarcoma.
    Branstetter D; Rohrbach K; Huang LY; Soriano R; Tometsko M; Blake M; Jacob AP; Dougall WC
    J Bone Oncol; 2015 Sep; 4(3):59-68. PubMed ID: 27556008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.